Stay updated on Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page shows a minor revision update from v3.3.3 to v3.3.4; this does not affect the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a Locations section with California as a study location and updated the page revision to v3.3.3.SummaryDifference0.2%

- Check44 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2. This appears to be an administrative metadata change rather than any modification to study details or content.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision: v3.3.1 was added and v3.2.0 was removed; this is a minor version-label update that does not alter study details or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedRemoved the government funding status notice/banner indicating potential delays and NIH operating status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check73 days agoChange DetectedNo additions or deletions are present; the page content remains unchanged.SummaryDifference0.4%

Stay in the know with updates to Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page.